Skip to main content

Published locations for Benefit-risk ratio favors 45 mg ponatinib as a starting dose in resistant CML-CP

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Benefit-risk ratio favors 45 mg ponatinib as a starting dose in resistant CML-CP

User login

  • Reset your password
  • /content/benefit-risk-ratio-favors-45-mg-ponatinib-starting-dose-resistant-cml-cp
  • /hematology-oncology/article/246641/cml/benefit-risk-ratio-favors-45-mg-ponatinib-starting-dose